Inflammation, glutamate, and glia: a trio of trouble in mood disorders
Increasing data indicate that inflammation and alterations in glutamate neurotransmission
are two novel pathways to pathophysiology in mood disorders. The primary goal of this …
are two novel pathways to pathophysiology in mood disorders. The primary goal of this …
Depression: an inflammatory illness?
R Krishnadas, J Cavanagh - Journal of Neurology, Neurosurgery & …, 2012 - jnnp.bmj.com
Major depressive disorder (MDD) is associated with significant morbidity and mortality.
Findings from preclinical and clinical studies suggest that psychiatric illnesses, particularly …
Findings from preclinical and clinical studies suggest that psychiatric illnesses, particularly …
R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine
J Zhang, S Li, K Hashimoto - Pharmacology Biochemistry and Behavior, 2014 - Elsevier
The N-methyl-d-aspartate (NMDA) receptor antagonist ketamine is one of the most attractive
antidepressants for treatment-resistant major depressive disorder (MDD). Ketamine (or RS …
antidepressants for treatment-resistant major depressive disorder (MDD). Ketamine (or RS …
Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies
TH Pham, AM Gardier - Pharmacology & therapeutics, 2019 - Elsevier
Ketamine, a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptor, displays
a fast antidepressant activity in treatment-resistant depression and in rodent models of …
a fast antidepressant activity in treatment-resistant depression and in rodent models of …
Toward a biosignature for suicide
MA Oquendo, GM Sullivan, K Sudol… - American Journal of …, 2014 - Am Psychiatric Assoc
Objective: Suicide, a major cause of death worldwide, has distinct biological underpinnings.
The authors review and synthesize the research literature on biomarkers of suicide, with the …
The authors review and synthesize the research literature on biomarkers of suicide, with the …
Antidepressant effects of TrkB ligands on depression-like behavior and dendritic changes in mice after inflammation
J Zhang, J Wu, Y Fujita, W Yao, Q Ren… - International Journal …, 2015 - academic.oup.com
Background: Brain-derived neurotrophic factor (BDNF) and its receptor, tropomyosin-related
kinase B (TrkB), signaling represent potential therapeutic targets for major depressive …
kinase B (TrkB), signaling represent potential therapeutic targets for major depressive …
Cognitive dysfunction in depression: neurocircuitry and new therapeutic strategies
JW Murrough, B Iacoviello, A Neumeister… - Neurobiology of learning …, 2011 - Elsevier
Major depressive disorder (MDD) is a disabling medical condition associated with significant
morbidity, mortality and public health costs. However, neurocircuitry abnormalities …
morbidity, mortality and public health costs. However, neurocircuitry abnormalities …
Density of GFAP-immunoreactive astrocytes is decreased in left hippocampi in major depressive disorder
JA Cobb, K O'Neill, J Milner, GJ Mahajan, TJ Lawrence… - Neuroscience, 2016 - Elsevier
Neuroimaging and postmortem studies of subjects with major depressive disorder (MDD)
reveal smaller hippocampal volume with lengthening duration of illness. Pathology in …
reveal smaller hippocampal volume with lengthening duration of illness. Pathology in …
Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo …
L Ibrahim, N DiazGranados, J Franco-Chaves… - …, 2012 - nature.com
The N-methyl-D-aspartate antagonist ketamine has rapid antidepressant effects in patients
with treatment-resistant major depression (TRD); these effects have been reported to last for …
with treatment-resistant major depression (TRD); these effects have been reported to last for …
The molecular neurobiology of chronic pain–induced depression
The increasing number of individuals with comorbidities poses an urgent need to improve
the management of patients with multiple co-existing diseases. Among these comorbidities …
the management of patients with multiple co-existing diseases. Among these comorbidities …